Alzheimer's drug embrace slows down as US doctors' reluctance grows

The adoption of the FDA-approved Alzheimer's drug, Leqimbi, has slowed down in the U.S. as more experts grow hesitant about the drugs cost, risks and efficacy.

Related Keywords

United States ,Georgia ,Wisconsin ,Boston ,Massachusetts ,Americans ,American ,Michael Greicius ,Lyn Castellano ,Donna Fick ,Priya Singhal ,Reisa Sperling ,Eric Widera ,Nathaniel Chin ,James Burke ,Alex Scott ,Anne White ,Suzanne Schindler ,Washington University In St ,Stanford University Center ,American Geriatrics Society ,Ohio State University ,University Of California San Francisco ,Journal Of The American Geriatrics Society ,Reuters ,Drug Administration ,Alzheimer Association ,University Of Wisconsin Alzheimer Disease Research Center ,Mass General Brigham ,Spherix Global ,Stanford University ,Memory Disorders ,California San Francisco ,Gerontological Nursing ,Jonathan Liss ,Disease Research Center ,American Geriatrics ,Washington University ,